Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Filament Health and currently in Phase I for Treatment Resistant Depression.

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker – Pharmaceutical Technology

MSD will now work with the FDA to update Keytruda’s label. Source: Shutterstock / Atmosphere1. Merck (MSD) has announced updated results with Keytruda (pembrolizumab) in

June 16, 2023

Breakthrough trial may improve diagnosis and life outcomes for patients with high-risk myeloma

Findings from a new medical trial, recently published in a prestigious scientific journal, may significantly improve life outcomes for patients with high-risk myeloma.

September 9, 2023

AI assurance labs intended to test health care technology have an equity problem

As leaders across federal agencies swiftly advance regulations for AI in health care, one proposal now seems too big to fail. That proposal is for

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.